Tumour localisation with a radioactively labelled reshaped human monoclonal antibody

V. Hird, M. Verhoeyen, R. A. Badley, D. Price, D. Snook, C. Kosmas, C. A. Gooden Bamias, C. Meares, J. P. Lavender, A. A. Epentos

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

A genetically reshaped human IgG1 monoclonal antibody (Hu2PLAP) with anti-tumour specificity, was radiolabelled with Indium-111 by chelation with a new macrocyclic compound (DOTA) which allows the production of stable radioimmunoconjugates for in vivo application. This was used to image seven patients with malignant disease, of whom two had been previously exposed to mouse monoclonal antibodies and had developed human anti-mouse antibodies (HAMA). Successful tumour localisation was seen in the four patients with active disease and antigen positive tumours. No patient showed any antibody responses against Hu2PLAP, but three out of six patients tested showed an immune response against the macrocycle DOTA. Reshaped human monoclonal antibodies with anti-tumour specificity may facilitate repeated administrations of radioactive antibodies, thus allowing new possibilities, both in the diagnosis and treatment of cancer.

Original languageEnglish (US)
Pages (from-to)911-914
Number of pages4
JournalBritish Journal of Cancer
Volume64
Issue number5
StatePublished - 1991
Externally publishedYes

Fingerprint

Monoclonal Antibodies
Neoplasms
Macrocyclic Compounds
Immunoconjugates
Indium
Neoplasm Antigens
Antibody Formation
Anti-Idiotypic Antibodies
Immunoglobulin G
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hird, V., Verhoeyen, M., Badley, R. A., Price, D., Snook, D., Kosmas, C., ... Epentos, A. A. (1991). Tumour localisation with a radioactively labelled reshaped human monoclonal antibody. British Journal of Cancer, 64(5), 911-914.

Tumour localisation with a radioactively labelled reshaped human monoclonal antibody. / Hird, V.; Verhoeyen, M.; Badley, R. A.; Price, D.; Snook, D.; Kosmas, C.; Gooden Bamias, C. A.; Meares, C.; Lavender, J. P.; Epentos, A. A.

In: British Journal of Cancer, Vol. 64, No. 5, 1991, p. 911-914.

Research output: Contribution to journalArticle

Hird, V, Verhoeyen, M, Badley, RA, Price, D, Snook, D, Kosmas, C, Gooden Bamias, CA, Meares, C, Lavender, JP & Epentos, AA 1991, 'Tumour localisation with a radioactively labelled reshaped human monoclonal antibody', British Journal of Cancer, vol. 64, no. 5, pp. 911-914.
Hird V, Verhoeyen M, Badley RA, Price D, Snook D, Kosmas C et al. Tumour localisation with a radioactively labelled reshaped human monoclonal antibody. British Journal of Cancer. 1991;64(5):911-914.
Hird, V. ; Verhoeyen, M. ; Badley, R. A. ; Price, D. ; Snook, D. ; Kosmas, C. ; Gooden Bamias, C. A. ; Meares, C. ; Lavender, J. P. ; Epentos, A. A. / Tumour localisation with a radioactively labelled reshaped human monoclonal antibody. In: British Journal of Cancer. 1991 ; Vol. 64, No. 5. pp. 911-914.
@article{5736508387024290b472e916fbec0637,
title = "Tumour localisation with a radioactively labelled reshaped human monoclonal antibody",
abstract = "A genetically reshaped human IgG1 monoclonal antibody (Hu2PLAP) with anti-tumour specificity, was radiolabelled with Indium-111 by chelation with a new macrocyclic compound (DOTA) which allows the production of stable radioimmunoconjugates for in vivo application. This was used to image seven patients with malignant disease, of whom two had been previously exposed to mouse monoclonal antibodies and had developed human anti-mouse antibodies (HAMA). Successful tumour localisation was seen in the four patients with active disease and antigen positive tumours. No patient showed any antibody responses against Hu2PLAP, but three out of six patients tested showed an immune response against the macrocycle DOTA. Reshaped human monoclonal antibodies with anti-tumour specificity may facilitate repeated administrations of radioactive antibodies, thus allowing new possibilities, both in the diagnosis and treatment of cancer.",
author = "V. Hird and M. Verhoeyen and Badley, {R. A.} and D. Price and D. Snook and C. Kosmas and {Gooden Bamias}, {C. A.} and C. Meares and Lavender, {J. P.} and Epentos, {A. A.}",
year = "1991",
language = "English (US)",
volume = "64",
pages = "911--914",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Tumour localisation with a radioactively labelled reshaped human monoclonal antibody

AU - Hird, V.

AU - Verhoeyen, M.

AU - Badley, R. A.

AU - Price, D.

AU - Snook, D.

AU - Kosmas, C.

AU - Gooden Bamias, C. A.

AU - Meares, C.

AU - Lavender, J. P.

AU - Epentos, A. A.

PY - 1991

Y1 - 1991

N2 - A genetically reshaped human IgG1 monoclonal antibody (Hu2PLAP) with anti-tumour specificity, was radiolabelled with Indium-111 by chelation with a new macrocyclic compound (DOTA) which allows the production of stable radioimmunoconjugates for in vivo application. This was used to image seven patients with malignant disease, of whom two had been previously exposed to mouse monoclonal antibodies and had developed human anti-mouse antibodies (HAMA). Successful tumour localisation was seen in the four patients with active disease and antigen positive tumours. No patient showed any antibody responses against Hu2PLAP, but three out of six patients tested showed an immune response against the macrocycle DOTA. Reshaped human monoclonal antibodies with anti-tumour specificity may facilitate repeated administrations of radioactive antibodies, thus allowing new possibilities, both in the diagnosis and treatment of cancer.

AB - A genetically reshaped human IgG1 monoclonal antibody (Hu2PLAP) with anti-tumour specificity, was radiolabelled with Indium-111 by chelation with a new macrocyclic compound (DOTA) which allows the production of stable radioimmunoconjugates for in vivo application. This was used to image seven patients with malignant disease, of whom two had been previously exposed to mouse monoclonal antibodies and had developed human anti-mouse antibodies (HAMA). Successful tumour localisation was seen in the four patients with active disease and antigen positive tumours. No patient showed any antibody responses against Hu2PLAP, but three out of six patients tested showed an immune response against the macrocycle DOTA. Reshaped human monoclonal antibodies with anti-tumour specificity may facilitate repeated administrations of radioactive antibodies, thus allowing new possibilities, both in the diagnosis and treatment of cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026001892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026001892&partnerID=8YFLogxK

M3 - Article

C2 - 1931615

AN - SCOPUS:0026001892

VL - 64

SP - 911

EP - 914

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -